ChlVPP chemotherapy in advanced Hodgkin's disease

J. J. McKendrick, G. M. Mead, J. Sweetenham, D. H. Jones, C. J. Williams, R. Ryall, J. M.A. Whitehouse

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Between March 1978 and January 1987 54 patients with advanced Hodgkin's disease (HD) or relapse following radiotherapy (RT) for Hodgkin's disease have been treated with combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). A subgroup of five patients with bulky mediastinal disease received mantle RT in addition to ChlVPP chemotherapy. Forty-two patients (77.8%) entered complete remission with 33 (61.0%) remaining in unmaintained remission and 44 (81.5%) alive at a median follow up of 51 months (range: 22-103). The treatment was generally well tolerated with minimal toxicity. ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.

Original languageEnglish (US)
Pages (from-to)557-561
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Issue number3
StatePublished - Mar 1989
Externally publishedYes

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'ChlVPP chemotherapy in advanced Hodgkin's disease'. Together they form a unique fingerprint.

Cite this